FDA-approved
Digestive & weight
Dasiglucagon
Evidence
FDA approved
Class
Long-lasting glucagon analog
KEY TAKEAWAY
Dasiglucagon is a stable glucagon analog with seven amino acid changes that keep it from clumping in solution. It is sold as Zegalogue. The FDA approved dasiglucagon (Zegalogue) in March 2021 for severe low blood sugar in people with diabetes aged 6 and older.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-lasting glucagon analog
Approved for
Severe low blood sugar in people with diabetes
Key fact
The FDA approved dasiglucagon (Zegalogue) in March 2021 for severe low blood sugar in people with diabetes aged 6 and older.
Route
Subcutaneous injection from a ready-to-use device
Evidence strength
FDA approved
Dasiglucagon is a stable glucagon analog with seven amino acid changes that keep it from clumping in solution. It is sold as Zegalogue.
It activates the glucagon receptor in the liver, which releases stored glucose into the blood.
The FDA approved dasiglucagon (Zegalogue) in March 2021 for severe low blood sugar in people with diabetes aged 6 and older.
Severe low blood sugar in people with diabetes.
Nausea, vomiting and headache are the most common effects, along with injection-site reactions.
U.S. FDA prescribing information for Dasiglucagon. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.